I am making an effort to increase my exposure to US stocks, and am considering adding a US healthcare position to augment my Canadian healthcare holdings of CSH.UN and GUD.
JNJ was my first thought, given its strong history, massive valuation, and diversification. However, I am (like many, I assume) concerned about its legal troubles; particularly given the severity of the issues that surround them. Moreover, it appears that said troubles may be present for quite a long time.
I am thinking long term (I am 36), am a "buy and hold" investor, and will not need the capital I would be deploying for the foreseeable future.
Do you feel as if this is a good entry point for JNJ (perhaps a half position to start), or would you wait to see how the legal situations unfold before considering this purchase? If the latter, is there another American healthcare stock you might recommend in its place?
Crh is dipping again and presently at the 2.80 level. I am getting punished resulting in a 60 percent loss. Are you guys now at the breaking point and removing this company from your growth portfolio. I am willing to wait it out , are you folks.?
Q: GUD is consistently a top recommendation as a growth stock. Have you spoken with GUD mgmt. lately to be able provide any additional info. as to when/how they are expecting to invest some of their cash and therefore move the stock in the next six months?
Without any news, it seems that GUD will continue to drift down as the 'bored' investors continue to sell.
With sells as it was going up, I am still about breakeven on CRH but it has dropped to 1% of my portfolio. I have lost confidence such that I won't put more in. I am, however, looking for additional healthcare exposure. Right now I am also holding JNJ (3%) Danaher (DHR, 4%) which is mostly medical/dental since the spin-off of Fortive. I have been thinking of exiting JNJ due to the price that they paid for their latest acquisition. It seems a little inconsistent with their historically very conservative nature.
Would you think that adding a 2.5-3% SIS or GUD is a better approach, or should I keep CRH given its longer term potential? I prefer to not watch my investments every day and have a diversified portfolio across market cap and Canada/US with a lot of multinational companies (like CCL in Canada and UL in the US, for instance).
Do you have any perspective on the JNJ acquisition? If so, please feel free to deduct two questions.
Q: Although I know you do not cover US companies, I was wondering about your take on JNJ. Especially given recent lawsuit activity with regard to their baby talcum powder and ovarian cancer, and possible upcoming class action lawsuit with regard to same. I know of at least one advisor recommending a sell due to this issue, but I am puzzled as there has been no negative reaction to the stock price so far. Your thoughts? Thanks.
Q: Hi Team, which would be a better buy at this point ABBV or NVO? Which offers more international exposure? For my us rrsp! Many thanks for your work. Sam
Q: Curious to know your take on recent weakness? Just market jitters and short term profit taking? Or, would investors be concerned about the company splitting in two and not wanting to be around for that event? Any backdrop on companies splitting in two being positive or not....I've seen some positive evidence but is such a company specific thing...
Thanks
T
Q: On Aug 17 you indicated "With the decline it is becoming an insignificant part of the portfolio so we need to review and either exit or add to it."
Given the recent news and price appreciation has your opinion changed?
Thanks
John
Q: Well, Gilead Sciences finally made there acquisition with their cash. Some say they should have brought Kite Pharma one year ago and overpay for it today. In addition, they say the Kite takeover will not be accretive for three years, What are your views and opinions on the deal that Gilead Sciences made for Kite Pharma?
Q: Any further developments in Mdx that would warrant buying it or is it still a wait & see situation because of its small size? Thanks as always for your great advice.
Dave